Abstract
Background: As new biomolecular targets for Alzheimer’s disease (AD) emerge, there is a tendency to regard these as mutually exclusive and in competition, culminating in declarations that since the “amyloid hypothesis is dead” it needs to be replaced by completely different theories. However, given the well-described role of misfolding peptides, particularly β-amyloid (Aβ), in the pathogenesis of AD, the need for a broad-based conceptualization of AD, coalescing different theories into a single harmonized explanation emerges as a viable alternative. Incorporating protein aggregation mechanisms of AD into a more widely-encompassing immunopathic model of AD could accomplish such a goal-a goal which could be achieved by repositioning the role of Aβ as an immunopeptide.
Conclusion: This review presents the concept that Aβ is an immunopeptide and that AD is an autoimmune disease in which Aβ is a key molecular player. Being a peptide with the capacity to alter immune function, Aβ is an immunopeptide; having both antimicrobial and immunomodulatory activities, Aβ is a host defense peptide; having most of the defining properties of cytokines, Aβ satisfies the broad definition of cytokine-the prototypic immunopeptide subtype. In addition to these immunoactivities, Aβ is also directly and independently cytotoxic to neurons by both necrotic and apoptotic mechanisms. Therefore, following brain exposure to immune-instigating stimuli, the innate immune system is activated, leading to the release of Aβ as an immunopeptide (functioning as a host defense peptide or cytokine), which subsequently inflicts a misdirected attack upon the host neurons-an autoimmune event.
Keywords: Alzheimer's disease, dementia, neuroinflammation, autoimmune, cytokine, antimicrobial peptide, amyloid-beta, immunopeptide.
Current Alzheimer Research
Title:β-Amyloid is an Immunopeptide and Alzheimer’s is an Autoimmune Disease
Volume: 18 Issue: 11
Author(s): Donald F. Weaver *
Affiliation:
- Krembil Research Institute, University Health Network, University of Toronto, Toronto, ON,Canada
Keywords: Alzheimer's disease, dementia, neuroinflammation, autoimmune, cytokine, antimicrobial peptide, amyloid-beta, immunopeptide.
Abstract:
Background: As new biomolecular targets for Alzheimer’s disease (AD) emerge, there is a tendency to regard these as mutually exclusive and in competition, culminating in declarations that since the “amyloid hypothesis is dead” it needs to be replaced by completely different theories. However, given the well-described role of misfolding peptides, particularly β-amyloid (Aβ), in the pathogenesis of AD, the need for a broad-based conceptualization of AD, coalescing different theories into a single harmonized explanation emerges as a viable alternative. Incorporating protein aggregation mechanisms of AD into a more widely-encompassing immunopathic model of AD could accomplish such a goal-a goal which could be achieved by repositioning the role of Aβ as an immunopeptide.
Conclusion: This review presents the concept that Aβ is an immunopeptide and that AD is an autoimmune disease in which Aβ is a key molecular player. Being a peptide with the capacity to alter immune function, Aβ is an immunopeptide; having both antimicrobial and immunomodulatory activities, Aβ is a host defense peptide; having most of the defining properties of cytokines, Aβ satisfies the broad definition of cytokine-the prototypic immunopeptide subtype. In addition to these immunoactivities, Aβ is also directly and independently cytotoxic to neurons by both necrotic and apoptotic mechanisms. Therefore, following brain exposure to immune-instigating stimuli, the innate immune system is activated, leading to the release of Aβ as an immunopeptide (functioning as a host defense peptide or cytokine), which subsequently inflicts a misdirected attack upon the host neurons-an autoimmune event.
Export Options
About this article
Cite this article as:
Weaver F. Donald *, β-Amyloid is an Immunopeptide and Alzheimer’s is an Autoimmune Disease, Current Alzheimer Research 2021; 18 (11) . https://dx.doi.org/10.2174/1567205018666211202141650
DOI https://dx.doi.org/10.2174/1567205018666211202141650 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Gene Silencing Mediated by Small Interfering RNAs in Mammalian Cells
Current Medicinal Chemistry Integrating Pathophysiology in Migraine: Role of the Gut Microbiome and Melatonin
Current Pharmaceutical Design Chemokines and Chemokine Receptors as Targets in the Therapy of Psoriasis
Current Drug Targets - Inflammation & Allergy Treating COPD in Older and Oldest Old Patients
Current Pharmaceutical Design Combination of Statin Plus Renin Angiotensin System Inhibition for the Prevention or the Treatment of Atherosclerotic Cardiovascular Disease
Current Pharmaceutical Design Clinically Relevant Genetic Variations in Drug Metabolizing Enzymes
Current Drug Metabolism Predictive Factors for Disability as Evaluated by the Health Assessment Questionnaire in Rheumatoid Arthritis: A Literature Review
Inflammation & Allergy - Drug Targets (Discontinued) Synthesis, Selective Cancer Cytotoxicity and Mechanistic Studies of Novel Analogs of Lantadenes
Anti-Cancer Agents in Medicinal Chemistry Novel Diagnostics R&D for Public Health and Personalized Medicine in Taiwan: Current State, Challenges and Opportunities
Current Pharmacogenomics and Personalized Medicine Protein Processing and Inflammatory Signaling in Cystic Fibrosis: Challenges and Therapeutic Strategies
Current Molecular Medicine Chimeric Antigen Receptor-Engineered T-Cells - A New Way and Era for Lymphoma Treatment
Recent Patents on Anti-Cancer Drug Discovery Migraine and Coronary Artery Disease: An Open Study on the Genetic Polymorphism of the 5, 10 Methylenetetrahydrofolate (MTHFR) and Angiotensin I-Converting Enzyme (ACE) Genes
Central Nervous System Agents in Medicinal Chemistry E-Cadherin Upregulation as a Therapeutic Goal in Cancer Treatment
Mini-Reviews in Medicinal Chemistry Improving DNA Vaccine Performance Through Vector Design
Current Gene Therapy Natural Products with Health Benefits from Marine Biological Resources
Current Organic Chemistry Benefits of Oral and Topical Administration of ROQUETTE Chlorella sp. on Skin Inflammation and Wound Healing in Mice
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Anticancer Face of Interferon Alpha (IFN-Alpha): From Biology to Clinical Results, with a Focus on Melanoma
Current Medicinal Chemistry Polyphenols: A Nutraceutical Approach Against Diseases
Recent Patents on Food, Nutrition & Agriculture Regulation of Innate Immunity Signaling and its Connection with Human Diseases
Current Drug Targets - Inflammation & Allergy Disease-Modifying Agents in the Treatment of Multiple Sclerosis: A Review of Long-Term Outcomes
CNS & Neurological Disorders - Drug Targets